These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1402429)

  • 1. Market power, collusion, and exclusion in health care antitrust enforcement.
    Spears JM
    J Med Assoc Ga; 1992 Sep; 81(9):499-507. PubMed ID: 1402429
    [No Abstract]   [Full Text] [Related]  

  • 2. Competition and antitrust enforcement in the changing pharmaceutical marketplace.
    Whitener MD
    Food Drug Law J; 1995; 50(2):301-7. PubMed ID: 10342998
    [No Abstract]   [Full Text] [Related]  

  • 3. Direct reimbursement and the conspiracy of silence.
    Plunkett LR
    N Y State Dent J; 1997 Oct; 63(8):6-9. PubMed ID: 9375505
    [No Abstract]   [Full Text] [Related]  

  • 4. The legal framework for effective competition.
    Berenson RA; Hastings DA; Kopit WG
    Baxter Health Policy Rev; 1996; 2():235-65. PubMed ID: 11066262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".
    Zain S
    Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229
    [No Abstract]   [Full Text] [Related]  

  • 6. Economic analysis in health care antitrust.
    Vita MG; Langenfeld J; Pautler P; Miller L
    J Contemp Health Law Policy; 1991; 7():73-115. PubMed ID: 10111250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitrust ruling may deter hospitals from challenging the market leader.
    Horty J
    Mod Healthc; 1986 May; 16(11):91-2. PubMed ID: 10276445
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceutical industry restructuring and new marketing approaches: enforcement responses.
    Mahinka SP; Sanzo KM
    Food Drug Law J; 1995; 50(2):313-25. PubMed ID: 10343000
    [No Abstract]   [Full Text] [Related]  

  • 9. Market definition key to antitrust regulations.
    Solovy A
    Hospitals; 1989 Oct; 63(19):74. PubMed ID: 2793118
    [No Abstract]   [Full Text] [Related]  

  • 10. Understanding antitrust: focus on the relevant market.
    Enders RJ
    Healthc Financ Manage; 1986 Feb; 40(2):25-32. PubMed ID: 10275004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. U.S. Supreme Court and Federal Trade Commission determine medicine is not a profession. Decision affects patient care.
    Gale AH
    Mo Med; 1997 Jul; 94(7):319-20. PubMed ID: 9223900
    [No Abstract]   [Full Text] [Related]  

  • 12. Enforcing reform. It's time for federal authorities to bring antitrust scrutiny to insurers.
    Balto D
    Mod Healthc; 2010 May; 40(21):24. PubMed ID: 20540212
    [No Abstract]   [Full Text] [Related]  

  • 13. Can HMOs wield market power? Assessing antitrust liability in the imperfect market for health care financing.
    Glassman ML
    Am Univ Law Rev; 1996 Oct; 46(1):91-147. PubMed ID: 10169685
    [No Abstract]   [Full Text] [Related]  

  • 14. Antitrust laws and zones of safety.
    Ross-Lee B; Kiss LE; Weiser MA
    J Am Osteopath Assoc; 1995 Jul; 95(7):429-34. PubMed ID: 7642406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Federal Trade Commission and physician practice.
    Graham J
    J Med Pract Manage; 2005; 20(5):259-62. PubMed ID: 15921139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis: prison? Health care providers, as they set up new business arrangements in this era of rising medical costs, risk running afoul of federal antitrust and antifraud laws.
    Kosterlitz J
    Natl J (Wash); 1989 Jun; 21(24):1576-7, 1582-4. PubMed ID: 10293560
    [No Abstract]   [Full Text] [Related]  

  • 17. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avoiding antitrust snags requires forethought and thorough market analysis.
    Engstrom P
    Med Netw Strategy Rep; 1995 May; 4(5):1-4. PubMed ID: 10153138
    [No Abstract]   [Full Text] [Related]  

  • 19. Establishing physician networks within evolving antitrust guidelines.
    Retchin TN; Retchin SM
    Clin Perform Qual Health Care; 1997; 5(3):140-5. PubMed ID: 10169186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.